These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. Palomo M; Diaz-Ricart M; Carbo C; Rovira M; Fernandez-Aviles F; Escolar G; Eissner G; Holler E; Carreras E Biol Blood Marrow Transplant; 2009 May; 15(5):537-46. PubMed ID: 19361745 [TBL] [Abstract][Full Text] [Related]
3. Predictive value of circulating angiopoietin-2 for endothelial damage-related complications in allogeneic hematopoietic stem cell transplantation. Ueda N; Chihara D; Kohno A; Tatekawa S; Ozeki K; Watamoto K; Morishita Y Biol Blood Marrow Transplant; 2014 Sep; 20(9):1335-40. PubMed ID: 24796281 [TBL] [Abstract][Full Text] [Related]
5. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Yoshihara S; Tateishi U; Ando T; Kunitoh H; Suyama H; Onishi Y; Tanosaki R; Mineishi S Bone Marrow Transplant; 2005 Jun; 35(12):1195-200. PubMed ID: 15852024 [TBL] [Abstract][Full Text] [Related]
6. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692 [TBL] [Abstract][Full Text] [Related]
7. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559 [TBL] [Abstract][Full Text] [Related]
9. Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Kong Y; Hu Y; Zhang XH; Wang YZ; Mo XD; Zhang YY; Wang Y; Han W; Xu LP; Chang YJ; Huang XJ Biol Blood Marrow Transplant; 2014 Aug; 20(8):1190-7. PubMed ID: 24792870 [TBL] [Abstract][Full Text] [Related]
10. Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: a retrospective study. Lazarevic VLj; Remberger M; Hägglund H; Hallböök H; Juliusson G; Kimby E; Malm C; Wahlin A; Omar H; Johansson JE Am J Hematol; 2011 Aug; 86(8):709-10. PubMed ID: 21761436 [No Abstract] [Full Text] [Related]
11. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation. Yoshimi A; Nannya Y; Sakata-Yanagimoto M; Oshima K; Takahashi T; Kanda Y; Motokura T; Chiba S; Kurokawa M Am J Hematol; 2008 Aug; 83(8):635-9. PubMed ID: 18506704 [TBL] [Abstract][Full Text] [Related]
12. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748 [TBL] [Abstract][Full Text] [Related]
13. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens. Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492 [TBL] [Abstract][Full Text] [Related]
14. Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Woywodt A; Scheer J; Hambach L; Buchholz S; Ganser A; Haller H; Hertenstein B; Haubitz M Blood; 2004 May; 103(9):3603-5. PubMed ID: 14715625 [TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience. Luo L; Zhang L; Cai B; Li H; Huang W; Jing Y; Zhu H; Zhao Y; Bo J; Wang Q; Han X; Yu L; Gao C Ann Transplant; 2014 Jan; 19():6-12. PubMed ID: 24399278 [TBL] [Abstract][Full Text] [Related]
16. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation. Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991 [TBL] [Abstract][Full Text] [Related]
18. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Palomo M; Diaz-Ricart M; Carbo C; Rovira M; Fernandez-Aviles F; Martine C; Ghita G; Escolar G; Carreras E Biol Blood Marrow Transplant; 2010 Jul; 16(7):985-93. PubMed ID: 20167280 [TBL] [Abstract][Full Text] [Related]
19. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience. Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652 [TBL] [Abstract][Full Text] [Related]